In the evolving landscape of diabetes management, novel therapies like semaglutide and retatrutide are gaining traction. These compounds, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist group, offer https://iwanozvp068370.actoblog.com/39847558/semaglutide-vs-retatrutide-a-novel-comparison-in-diabetes-management